UK
UK Agrees to Increase Drug Spending by 25% to Avoid US Pharma Tariffs
UK; United States; drug spending; pharmaceutical tariffs; trade deal; medicine pricing; Trump administration; pharma companies
Nxera Pharma to Cut 15% of Workforce in Japan and UK as Part of Restructuring Plan
Nxera Pharma; workforce reduction; restructuring; Japan; UK; R&D operations; profitability; GPCR pipeline; organizational optimization
UK Proposes Raising Payment Scheme for Branded Medicines to Nearly 25% Amid Industry Pushback
UK medicine pricing; NHS spending; statutory scheme; drugmakers; payment percentage; pharmaceutical rebates; industry response; consultation 2025
Barinthus Biotherapeutics Announces Reverse Merger with Clywedog Therapeutics to Form New Metabolic Disease-Focused Company
Barinthus Biotherapeutics; Reverse Merger; Clywedog Therapeutics; Metabolic Diseases; Autoimmune Diseases; Topco; Shareholder Ownership Structure; UK Scheme of Arrangement; Delaware Merger; Self-Tender Offer; Lock-Up Period; Board Composition
AstraZeneca Plans Direct US Stock Listing While Maintaining UK Headquarters
AstraZeneca; US stock listing; NYSE; London Stock Exchange; Nasdaq Stockholm; American Depositary Receipts; capital markets; pharmaceutical industry; shareholders; UK headquarters
Bristol Myers Squibb to Launch Schizophrenia Drug Cobenfy in UK at US Price
Bristol Myers Squibb; Cobenfy; schizophrenia; UK launch; drug pricing; US list price; NHS; cholinergic receptors; antipsychotic; 2026
A Concerning Pattern: Pharma Mulls UK Divestments as Government Action Lags in Life Sciences
UK life sciences; pharmaceutical divestment; Merck; AstraZeneca; Sanofi; Eli Lilly; R&D investment; drug pricing; government policy; NHS drug spending
AstraZeneca Pauses £200M Expansion in UK Amid Pharma Uncertainty
AstraZeneca; UK Pharma; Investment; Cambridge; Expansion Pause
Eli Lilly Pauses UK Biotech Incubator Plans Amid Concerns Over NHS Drug Pricing
Eli Lilly; Gateway Labs; UK biotech incubator; pause; investment; NHS drug spending; life sciences; biotech industry; government funding; pharmaceutical innovation